Literature DB >> 11511986

Recovery from cyclosporine-associated arteriolopathy in childhood nephrotic syndrome.

K Hamahira1, K Iijima, R Tanaka, H Nakamura, N Yoshikawa.   

Abstract

Cyclosporine (CS) is well recognized to be effective in the treatment of children with steroid-dependent and steroid-resistant nephrotic syndrome (NS), but its use can result in chronic nephrotoxicity. The histological changes that occur after CS discontinuation are unknown. Therefore, we examined the histological changes [CS-associated arteriolopathy (CAA), tubulointerstitial lesions, and focal glomerular lesions] in renal biopsy specimens after the drug had been discontinued in eight children with idiopathic nephrotic syndrome (NS). These children had been treated with long-term moderate-dose CS and had shown mild-to-moderate chronic CS nephrotoxicity. The degree of CAA improved significantly after CS discontinuation (mean CAA grade from 1.30+/-0.46 to 0.25+/-0.46, P=0.028). CAA disappeared in six of these children after CS discontinuation. However, the tubulointerstitial lesions and the focal glomerular lesions did not change after CS discontinuation. In conclusion, in children with idiopathic NS, CAA is improved by discontinuation of CS, but tubulointerstitial changes and focal glomerular lesions do not regress with drug discontinuation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11511986     DOI: 10.1007/s004670100646

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  9 in total

1.  Impact of interrupted cyclosporine treatment on the development of chronic nephrotoxicity in children with steroid-dependent nephrotic syndrome.

Authors:  Shuichiro Fujinaga; Yasuko Urushihara
Journal:  Pediatr Nephrol       Date:  2017-05-31       Impact factor: 3.714

2.  The significance of tubulointerstitial lesions in childhood Henoch-Schönlein nephritis.

Authors:  Beom Jin Lim; Jae Il Shin; Sung-Eun Choi; Hyechang Rhim; Jae Seung Lee; Pyung Kil Kim; Hyeon Joo Jeong; Ji Hong Kim
Journal:  Pediatr Nephrol       Date:  2016-05-27       Impact factor: 3.714

3.  Cyclosporine A vs. methylprednisolone for Henoch-Schönlein nephritis: a randomized trial.

Authors:  Outi Jauhola; Jaana Ronkainen; Helena Autio-Harmainen; Olli Koskimies; Marja Ala-Houhala; Pekka Arikoski; Tuula Hölttä; Timo Jahnukainen; Jukka Rajantie; Timo Ormälä; Matti Nuutinen
Journal:  Pediatr Nephrol       Date:  2011-05-28       Impact factor: 3.714

4.  Cyclosporin A may cause injury to undifferentiated glomeruli persisting in patients with Alport syndrome.

Authors:  Keisuke Sugimoto; Shinsuke Fujita; Tomoki Miyazawa; Hitomi Nishi; Takuji Enya; Akane Izu; Norihisa Wada; Naoki Sakata; Mitsuru Okada; Tsukasa Takemura
Journal:  Clin Exp Nephrol       Date:  2013-07-05       Impact factor: 2.801

5.  Nephrotoxicity in children with frequently relapsing nephrotic syndrome receiving long-term cyclosporine treatment.

Authors:  Yuko Hamasaki; Fumiyo Komaki; Kenji Ishikura; Riku Hamada; Tomoyuki Sakai; Hiroshi Hataya; Kentaro Ogata; Takashi Ando; Masataka Honda
Journal:  Pediatr Nephrol       Date:  2017-04-04       Impact factor: 3.714

6.  Cyclosporine therapy monitored with abbreviated area under curve in nephrotic syndrome.

Authors:  Stefano Rinaldi; Antonella Sesto; Paola Barsotti; Tullio Faraggiana; Francesco Sera; Gianfranco Rizzoni
Journal:  Pediatr Nephrol       Date:  2004-11-25       Impact factor: 3.714

7.  Independent risk factors for chronic cyclosporine induced nephropathy in children with nephrotic syndrome.

Authors:  S Fujinaga; K Kaneko; T Muto; Y Ohtomo; H Murakami; Y Yamashiro
Journal:  Arch Dis Child       Date:  2006-05-02       Impact factor: 3.791

8.  Expression of fibrosis-associated molecules in IgA nephropathy treated with cyclosporine.

Authors:  Beom Jin Lim; Ji Hong Kim; Soon Won Hong; Hyeon Joo Jeong
Journal:  Pediatr Nephrol       Date:  2008-12-09       Impact factor: 3.714

9.  Long-term follow-up after cyclophosphamide and cyclosporine-A therapy in steroid-dependent and -resistant nephrotic syndrome.

Authors:  Viktória Sümegi; Ibolya Haszon; Csaba Bereczki; Ferenc Papp; Sándor Túri
Journal:  Pediatr Nephrol       Date:  2008-03-07       Impact factor: 3.714

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.